Cohance Lifesciences' API Unit-IV clears USFDA inspection
Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India, from 03 March 2025 to 07 March 2025.
The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
17 hours ago
- Time of India
Demolition of century-old N C Ghosh Institute begins to make way for elevated road project
1 2 Patna: Demolition teams on Thursday razed a major portion of the 95-year-old N C Ghosh Institute, established in the pre-British era under the East India Railway (EIR) at Khagaul near Danapur station, to make way for the upcoming Khagaul-Bihta elevated road project. The institute served as a focal point for community gatherings, indoor games and festive events. Known especially for hosting grand Anglo-Indian Christmas celebrations in its heyday, the institute held deep cultural and historical significance for the local populace, said an old timer Alok Das. However, as urban infrastructure expands to meet growing demands, the heritage structure was identified as a major obstruction along the alignment of the elevated corridor. In a bid to balance development with cultural continuity, the railways has announced plans to construct a state-of-the-art facility little distance away from the existing institute on a vacant land in the railway colony area. Talking to this newspaper here on Friday Danapur divisional railway manager ( DRM ) Jayant Kumar Choudhary confirmed that the railways would build a new three-storey multi-purpose hall hardly at a little distance away from the existing institute . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Esse novo alarme com câmera é quase gratuito em São Gonçalo (consulte o preço) Alarmes Undo "The ground floor will be developed as a parking facility, the first floor will house 20 rooms for various purposes, and the top floor will feature a large hall with a seating capacity of 400 to 500 people, equipped with all modern amenities," the DRM said. "The govt has already disbursed compensation for the acquisition of land. The new facility is expected to be constructed at an estimated cost of Rs 12 crore for which tenders are being floated and work is expected to commence soon after the bidding process is complete," DRM said, adding the new multipurpose hall which will be completed in two years from now, aims to continue the legacy of the N C Ghosh Institute by offering an upgraded venue for cultural events, community programme and indoor activities, preserving its spirit in a modern avatar. Locals, mostly theatre artists like Sudhir Madhukar and Nawab Alam, have expressed mixed reactions while some lament the loss of a historic landmark, others welcomed the prospect of improved infrastructure and recreational facilities in the area. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Hans India
a day ago
- Hans India
Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich
New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europe and emerging markets in the second half of the current financial year, it added. Wockhardt said it has also filed for approval of Zaynich with the Drug Controller General of India (DCGI) and expects to launch the product in the domestic market in the second half of the current fiscal. The antibiotic, to be used against gram-negative infections, is expected to help 11 lakh cases in India alone, the Mumbai-based drug maker said.
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
